Role of Blastomyces BAD-1 IgG Enzyme Immunoassay (EIA) for the diagnosis of blastomycosis in persons residing in an endemic area
Medical Mycology · 2026
DOI: 10.1093/mmy/myag002 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Medical Mycology, 2026. Verfasst von Gregory M Gauthier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Wisconsin School of Medicine & Public Health, University of Wisconsin-Madison, Madison, WI, USA. Hauptthemen laut MEDLINE: Blastomycosis, Blastomyces, Immunoglobulin G, Antibodies, Fungal. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Blastomyces species complex causes infection in persons with intact and impaired immune defenses. The diagnosis of blastomycosis is challenging because it mimics infectious and non-infectious diseases. Blastomyces adhesin-1 (BAD-1) protein is a major virulence factor in B. dermatitidis and B. gilchristii and induces a humoral immune response during infection. The goal of this retrospective, case-control study conducted at the University of Wisconsin–Madison is to investigate the test characteristics of the newly developed second generation BAD-1 IgG Enzyme Immunoassay (EIA) antibody test for the diagnosis of blastomycosis. The study was performed in an endemic area in a diverse patient population including persons with underlying immunocompromise. Thirty-six case patients with proven or probable blastomycosis were compared to 370 controls. Serum BAD-1 IgG was positive in 50% of the case patients and in 9.7% of the controls, which resulted in a sensitivity of 50% and specificity of 90.2%. The highest sensitivity (80%) occurred in non-immunocompromised persons with chronic blastomycosis and the lowest sensitivity occurred in those with acute blastomycosis (35.0%) or immunocompromise (37.5%). Sensitivity was not influenced by dissemination or severity of disease. In conclusion, this study demonstrates that the BAD-1 IgG EIA can serve as adjunctive test for the diagnosis of blastomycosis in select patient populations living in regions endemic for blastomycosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, University of Wisconsin School of Medicine & Public Health, University of Wisconsin-Madison, Madison, WI, USA.
- University of Wisconsin School of Medicine & Public Health, University of Wisconsin-Madison, Madison, WI, USA.
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.
- Miravista Diagnostics, Indianapolis, Indiana, USA.
ORCID-Profile: Gregory M Gauthier
Förderung
- NIAID NIH HHS
- National Institute of Health
Zitieren
APA
Gauthier, G. M., Hollnagel, F., Klein, B., Sterkel, A., Shanna, N., & Wheat, J. (2026). Role of Blastomyces BAD-1 IgG Enzyme Immunoassay (EIA) for the diagnosis of blastomycosis in persons residing in an endemic area. Medical Mycology. https://doi.org/10.1093/mmy/myag002
Vancouver
Gauthier GM, Hollnagel F, Klein B, Sterkel A, Shanna N, Wheat J. Role of Blastomyces BAD-1 IgG Enzyme Immunoassay (EIA) for the diagnosis of blastomycosis in persons residing in an endemic area. Medical Mycology. 2026. doi:10.1093/mmy/myag002
BibTeX
@article{Gauthier2026,
author = {Gauthier, Gregory M and Hollnagel, Fauzia and Klein, Bruce and Sterkel, Alana and Shanna, Noveroske and Wheat, Joseph},
title = {Role of Blastomyces BAD-1 IgG Enzyme Immunoassay (EIA) for the diagnosis of blastomycosis in persons residing in an endemic area},
journal = {Medical Mycology},
year = {2026},
doi = {10.1093/mmy/myag002}
}
EUVIMED